文献速递临床生化临床血液与体液质量管理与危急值

高剂量抗坏血酸对血气、即时检验和自动化临床化学检测的干扰

Interference of high dose ascorbate in blood gas, point-of-care, and automated clinical chemistry assays.
PubMed 文献 · Clin Chim Acta · 2026-06-02

研究将抗坏血酸钠以0-200 mg/dL加入残余患者血清和全血,评估其对多种分析平台的干扰。结果发现抗坏血酸对乳酸、脂肪酶、胆固醇、甘油三酯及多个葡萄糖检测平台存在干扰,为实验室和临床医生提供参考。

要点

  • 高浓度抗坏血酸可干扰乳酸、脂肪酶、胆固醇、甘油三酯及多个葡萄糖检测平台。
  • 血清样本在Abbott临床化学和免疫分析仪上检测,全血样本在血气、即时检验和血糖仪上检测。
  • 使用缓冲抗坏血酸可避免因pH扰动导致的虚假结果。

核心结论

  • 高浓度抗坏血酸对乳酸、脂肪酶、胆固醇、甘油三酯及多个葡萄糖检测平台存在干扰。

研究设计与样本

  • 将抗坏血酸钠以0-200 mg/dL加入残余患者血清,在Abbott ARCHITECT c8000临床化学和i2000SR免疫分析仪上检测。
  • 全血研究在Nova STAT PROFILE pHOX Ultra系统、Abbott i-STAT 1系统(Chem8+卡)和Roche Accu-Chek Inform II血糖仪上进行,抗坏血酸钠浓度为0-200 mg/dL。

主要发现

  • 检测到抗坏血酸对乳酸、脂肪酶、胆固醇、甘油三酯和多个葡萄糖检测平台存在干扰。

临床怎么用

  • 实验室人员和临床医生应了解高浓度抗坏血酸对上述检测项目的干扰,以正确解读接受此类治疗患者的检测结果。

局限性

  • 许多已发表研究使用未缓冲的抗坏血酸加入血液,可能因pH扰动导致虚假结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ascorbic acid (AA) has been under investigation for a variety of therapeutic indications, including cancer treatment and sepsis. New investigational treatments utilize much higher concentrations than historical studies, leading to uncertainty about the effects on clinical testing platforms. Published work indicates AA interferes with lipid and point-of-care glucometer measurements, however a comprehensive evaluation of potential interference at these higher concentrations with a unified experimental design is lacking. Additionally, many of the published studies use unbuffered AA spiked into blood which may cause spurious results due to pH disturbances. The objective of this study is an evaluation of high concentrations of sodium ascorbate interference on various analysis platforms. Sodium ascorbate was spiked into residual patient serum at 0-200 mg/dL. These samples were analyzed in triplicate on the Abbott ARCHITECT c8000 clinical chemistry and i2000SR immunoassay analyzers for a large menu of analytes. Whole blood studies were conducted at 0-200 mg/dL sodium ascorbate on the Nova STAT PROFILE pHOX Ultra system co-oximetry assays, Abbott i-STAT 1 System using the i-STAT Chem8+ cartridge, and a Roche Accu-Chek Inform II System glucometer. Assay interference by ascorbate was detected for lactate, lipase, cholesterol, triglycerides, and several glucose assay platforms. This multi-platform study at high concentrations of ascorbate for a variety of clinical chemistry assays will be of use to laboratorians and clinicians who have patients undergoing these treatments.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Williams GR, Gin G. Interference of high dose ascorbate in blood gas, point-of-care, and automated clinical chemistry assays. Clin Chim Acta. 2026. PMID: 42235732. doi:10.1016/j.cca.2026.121141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。